

# Konstantinos Stavropoulos

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5052600/konstantinos-stavropoulos-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79  
papers

589  
citations

12  
h-index

20  
g-index

92  
ext. papers

805  
ext. citations

5.8  
avg, IF

4.39  
L-index

#	Paper	IF	Citations
79	Impact of Primary Aldosteronism in Resistant Hypertension.. <i>Current Hypertension Reports</i> , <b>2022</b> , 1	4.7	0
78	Assessment of skin microcirculation in primary aldosteronism: impaired microvascular responses compared to essential hypertensives and normotensives. <i>Journal of Human Hypertension</i> , <b>2021</b> ,	2.6	3
77	The Impact of Various Blood Pressure Measurements on Cardiovascular Outcomes. <i>Current Vascular Pharmacology</i> , <b>2021</b> , 19, 313-322	3.3	0
76	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. <i>Current Vascular Pharmacology</i> , <b>2021</b> , 19, 323-342	3.3	8
75	Renal tubular transport protein regulation in primary aldosteronism: can large-scale proteomic analysis offer a new insight?. <i>Journal of Human Hypertension</i> , <b>2021</b> , 35, 825-827	2.6	2
74	Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria. <i>American Journal of Cardiology</i> , <b>2021</b> , 138, 116-118	3	0
73	Hypertension in Pregnancy: Unanswered Questions. <i>Current Pharmaceutical Design</i> , <b>2021</b> , 27, 3795-3803	3.3	0
72	COVID-19: The Waterloo of governments, healthcare systems, and large health organizations. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 77, 153-155	3.9	4
71	Update of the position paper on arterial hypertension and erectile dysfunction. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 1220-1234	1.9	9
70	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. <i>Journal of Clinical Hypertension</i> , <b>2020</b> , 22, 562-571	2.3	14
69	Treatment strategies for hypertension in patients with type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 1241-1252	4	5
68	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. <i>Journal of Clinical Hypertension</i> , <b>2020</b> , 22, 572-584	2.3	17
67	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. <i>Current Vascular Pharmacology</i> , <b>2020</b> , 18, 125-138	3.3	3
66	Pharmacological Management of Diabetic Nephropathy. <i>Current Vascular Pharmacology</i> , <b>2020</b> , 18, 139-147	3.3	1
65	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 887-893	3	2
64	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. <i>American Journal of Cardiology</i> , <b>2020</b> , 137, 133-135	3	1
63	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. <i>Journal of Human Hypertension</i> , <b>2020</b> , 34, 764-767	2.6	16

62	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. <i>Current Hypertension Reports</i> , <b>2020</b> , 22, 90	4.7	22
61	Primary Aldosteronism: Novel Insights. <i>Current Hypertension Reviews</i> , <b>2020</b> , 16, 19-23	2.3	3
60	Hypertension in Metabolic Syndrome: Novel Insights. <i>Current Hypertension Reviews</i> , <b>2020</b> , 16, 12-18	2.3	14
59	Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus. <i>Vascular Health and Risk Management</i> , <b>2019</b> , 15, 365-373	4.4	6
58	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. <i>Journal of Sexual Medicine</i> , <b>2019</b> , 16, 1199-1211	1.1	4
57	Physical Activity, Fitness, and Sexual Dysfunction <b>2019</b> , 373-387		
56	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 241-251	4.1	3
55	Now That Renal Denervation Works, How Do We Proceed?. <i>Circulation Research</i> , <b>2019</b> , 124, 693-695	15.7	11
54	Insomnia and hypertension: A misty landscape. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 835-837	2.3	2
53	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. <i>Current Vascular Pharmacology</i> , <b>2019</b> , 17, 425-428	3.3	4
52	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. <i>Heart Failure Clinics</i> , <b>2019</b> , 15, 519-530	3.3	0
51	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 1578-1579	2.3	0
50	Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease. <i>Clinical and Molecular Hepatology</i> , <b>2019</b> , 25, 331-332	6.9	
49	Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. <i>Polish Archives of Internal Medicine</i> , <b>2019</b> , 129, 648-649	1.9	
48	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. <i>International Journal of Cardiology: Hypertension</i> , <b>2019</b> , 3, 100022	1.6	
47	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , <b>2019</b> , 158, 107927	7.4	10
46	Determinants of pulse wave velocity index and potential implementations. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 1493-1495	2.3	1
45	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 589-591	2.3	1

44	Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 967-968	59.2	12
43	Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 701	1.9	2
42	Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 255-257	2.3	3
41	Diabetes and lipid metabolism. <i>Hormones</i> , <b>2018</b> , 17, 61-67	3.1	81
40	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 634-636	2.3	2
39	The potential role of statins in treating liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 331-339	4.2	10
38	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 469-471	2.3	2
37	Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 65-68	2.3	8
36	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 942-948	2.3	5
35	Pseudohyperaldosteronism due to mumijo consumption during pregnancy: a licorice-like syndrome. <i>Gynecological Endocrinology</i> , <b>2018</b> , 34, 1019-1021	2.4	12
34	Letter by Stavropoulos et al Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control". <i>Circulation</i> , <b>2018</b> , 137, 2664-2665	16.7	1
33	Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 1879-1886	3.3	11
32	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 4587-4592	3.3	18
31	The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 5517-5524	3.3	3
30	Mineralocorticoid Receptor Antagonists in Primary Aldosteronism. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 5508-5516	3.3	4
29	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 130-142	3.3	36
28	Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 239-245	3.3	10
27	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 246-253	3.3	49

26	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 276-288	3.3	4
25	SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. <i>Current Clinical Pharmacology</i> , <b>2018</b> , 13, 261-272	2.5	10
24	Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , <b>2018</b> , 18, 104-113	1.1	2
23	Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , <b>2018</b> , 18, 94-103	1.1	3
22	Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 3647-3653	3.3	7
21	Antihypertensive drug treatment: the real-life challenge. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 115-117	1.1	1
20	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. <i>Open Cardiovascular Medicine Journal</i> , <b>2018</b> , 12, 29-40	0.7	15
19	Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , <b>2018</b> , 18, 120-126	1.1	2
18	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 249-253	5.5	30
17	Hematocrit and Stroke: A Forgotten and Neglected Link?. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2017</b> , 43, 591-598	5.3	8
16	Blood pressure and cardiovascular outcomes: a closer look. <i>Lancet, The</i> , <b>2017</b> , 389, 1295-1296	4.0	1
15	Abnormal blood pressure dipping in diabetic kidney disease: A black-race nightmare?. <i>Journal of Clinical Hypertension</i> , <b>2017</b> , 19, 1336-1338	2.3	3
14	The effect of SGLT2 inhibitors on cardiovascular events and renal function. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 1251-1261	3.8	9
13	Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 1393	11.5	0
12	Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients?. <i>Journal of Clinical Hypertension</i> , <b>2017</b> , 19, 798-800	2.3	6
11	Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 2502	59.2	4
10	SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 1510-1521	3.3	12
9	Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 1540-1550	3.3	12

8	Depression in hypertensive patients: the role of comorbidities. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 1441	1.9	1
7	PATHWAY-2: spironolactone for resistant hypertension. <i>Lancet, The</i> , <b>2016</b> , 387, 1371-1372	4.0	
6	Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?. <i>American Journal of Hypertension</i> , <b>2016</b> , 29, 662	2.3	4
5	Testosterone Treatment in Older Men. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 90	59.2	13
4	Letter by Imprialos et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". <i>Circulation</i> , <b>2016</b> , 134, e5-6	16.7	
3	Renin-Angiotensin System Inhibitors: Do They Have the Same Impact at All Ages?. <i>Journal of Clinical Hypertension</i> , <b>2016</b> , 18, 828	2.3	1
2	Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. <i>Journal of Clinical Hypertension</i> , <b>2016</b> , 18, 1073	2.3	3
1	Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials; are there any drug differences?. <i>Journal of Diabetes and Metabolic Disorders</i> , 1	2.5	